{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:05:51Z","timestamp":1794963951719,"version":"4.9.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"8136","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,10,15]]},"DOI":"10.1038\/s41586-026-10925-6","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:02:14Z","timestamp":1786546934000},"page":"774-784","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Biomarkers of nivolumab benefit in resectable non-small cell lung cancer"],"prefix":"10.1038","volume":"658","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3008-5407","authenticated-orcid":false,"given":"Tina","family":"Cascone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2708-1309","authenticated-orcid":false,"given":"Jonathan D.","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6961-8421","authenticated-orcid":false,"given":"Jie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubos B.","family":"Petruzelka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Pujol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmila","family":"de Oliveira Muniz Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5351-4234","authenticated-orcid":false,"given":"Tudor-Eliade","family":"Ciuleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Bohnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3679-4864","authenticated-orcid":false,"given":"Yasutaka","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8273-4395","authenticated-orcid":false,"given":"Janis M.","family":"Taube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8040-5205","authenticated-orcid":false,"given":"Julie Stein","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinthya Coronado","family":"Erdmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Meadows-Shropshire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7137-3953","authenticated-orcid":false,"given":"Jaclyn","family":"Neely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1448-6633","authenticated-orcid":false,"given":"Virginia","family":"Ip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Han","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padma","family":"Sathyanarayana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeena","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven I.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Lucherini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathanial","family":"Eddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6315-7919","authenticated-orcid":false,"given":"Mariano","family":"Provencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"10925_CR1","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","volume":"390","author":"T Cascone","year":"2024","unstructured":"Cascone, T. et al. Perioperative nivolumab in resectable lung cancer. N. Engl. J. Med. 390, 1756\u20131769 (2024).","journal-title":"N. Engl. J. Med."},{"key":"10925_CR2","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde, P. M. et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. 386, 1973\u20131985 (2022).","journal-title":"N. Engl. J. Med."},{"key":"10925_CR3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa2502931","volume":"393","author":"PM Forde","year":"2025","unstructured":"Forde, P. M. et al. Overall survival with neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. 393, 741\u2013752 (2025).","journal-title":"N. Engl. J. Med."},{"key":"10925_CR4","unstructured":"US Food and Drug Administration. Opdivo (nivolumab): highlights of prescribing information. FDA https:\/\/nctr-crs.fda.gov\/fdalabel\/services\/spl\/set-ids\/f570b9c4-6846-4de2-abfa-4d0a4ae4e394\/spl-doc (2025)."},{"key":"10925_CR5","unstructured":"European Medicines Agency. Opdivo (nivolumab): summary of product characteristics. EMA https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opdivo-epar-product-information_en.pdf (2025)."},{"key":"10925_CR6","unstructured":"Medical and Healthcare Products Regulatory Agency. Opdivo (nivolumab): summary of product characteristics. MHRA https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/94f75cd2f341119d67cec446e2d8161ebdbf8bf8 (2025)."},{"key":"10925_CR7","unstructured":"Therapeutic Goods Administration. Opdivo (nivolumab): product information. TGA https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2016-PI-01052-1&d=20250407172310101 (2025)."},{"key":"10925_CR8","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach, J. V. et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N. Engl. J. Med. 389, 1672\u20131684 (2023).","journal-title":"N. Engl. J. Med."},{"key":"10925_CR9","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.jtho.2024.09.069","volume":"19","author":"JV Heymach","year":"2024","unstructured":"Heymach, J. V. et al. Perioperative durvalumab for resectable NSCLC (R-NSCLC): updated outcomes from the phase 3 AEGEAN trial. J. Thorac. Oncol. 19, S38\u2013S39 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"10925_CR10","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","volume":"404","author":"JD Spicer","year":"2024","unstructured":"Spicer, J. D. et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 404, 1240\u20131252 (2024).","journal-title":"Lancet"},{"key":"10925_CR11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee, H. et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N. Engl. J. Med. 389, 491\u2013503 (2023).","journal-title":"N. Engl. J. Med."},{"key":"10925_CR12","doi-asserted-by":"publisher","first-page":"S1607","DOI":"10.1016\/j.annonc.2025.09.079","volume":"36","author":"H Wakelee","year":"2025","unstructured":"Wakelee, H. et al. Perioperative pembrolizumab in early-stage non-small- cell lung cancer (NSCLC): 5-year follow-up from KEYNOTE-671. Ann. Oncol. 36, S1607\u2013S1608 (2025).","journal-title":"Ann. Oncol."},{"key":"10925_CR13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.annonc.2025.11.017","volume":"37","author":"C Wang","year":"2026","unstructured":"Wang, C. et al. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial. Ann. Oncol. 37, 544\u2013554 (2026).","journal-title":"Ann. Oncol."},{"key":"10925_CR14","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","volume":"13","author":"T Cascone","year":"2023","unstructured":"Cascone, T. et al. Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II NeoCOAST platform trial. Cancer Discov. 13, 2394\u20132411 (2023).","journal-title":"Cancer Discov."},{"key":"10925_CR15","doi-asserted-by":"publisher","first-page":"8046","DOI":"10.1200\/JCO.2025.43.16_suppl.8046","volume":"43","author":"T Cascone","year":"2025","unstructured":"Cascone, T. et al. Neoadjuvant durvalumab (D) + chemotherapy (CT) + novel anticancer agents and adjuvant D \u00b1 novel agents in resectable non-small-cell lung cancer (NSCLC): updated outcomes from NeoCOAST-2. J. Clin. Oncol. 43, 8046 (2025).","journal-title":"J. Clin. Oncol."},{"key":"10925_CR16","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S1470-2045(24)00498-4","volume":"25","author":"M Provencio","year":"2024","unstructured":"Provencio, M. et al. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial. Lancet Oncol. 25, 1453\u20131464 (2024).","journal-title":"Lancet Oncol."},{"key":"10925_CR17","doi-asserted-by":"publisher","first-page":"S1239","DOI":"10.1016\/j.annonc.2024.08.2290","volume":"35","author":"M Reck","year":"2024","unstructured":"Reck, M. et al. Associations of ctDNA clearance (CL) during neoadjuvant Tx with pathological response and event-free survival (EFS) in pts with resectable NSCLC (R-NSCLC): expanded analyses from AEGEAN. Ann. Oncol. 35, S1239 (2024).","journal-title":"Ann. Oncol."},{"key":"10925_CR18","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1200\/JCO.2025.43.16_suppl.8009","volume":"43","author":"M Reck","year":"2025","unstructured":"Reck, M. et al. Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial. J. Clin. Oncol. 43, 8009 (2025).","journal-title":"J. Clin. Oncol."},{"key":"10925_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.lungcan.2020.11.005","volume":"151","author":"T Tsitsias","year":"2021","unstructured":"Tsitsias, T. et al. New N1\/N2 classification and lobe specific lymphatic drainage: impact on survival in patients with non-small cell lung cancer treated with surgery. Lung Cancer 151, 84\u201390 (2021).","journal-title":"Lung Cancer"},{"key":"10925_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s43018-025-01104-z","volume":"7","author":"M Provencio","year":"2026","unstructured":"Provencio, M. et al. Clinical outcomes with perioperative nivolumab by nodal status among patients with stage III resectable NSCLC from the phase 3 CheckMate 77T study. Nat. Cancer 7, 169\u2013181 (2026).","journal-title":"Nat. Cancer"},{"key":"10925_CR21","doi-asserted-by":"publisher","first-page":"8011","DOI":"10.1200\/JCO.2024.42.16_suppl.8011","volume":"42","author":"J Heymach","year":"2024","unstructured":"Heymach, J. et al. Outcomes with perioperative durvalumab (D) in pts with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): an exploratory subgroup analysis of AEGEAN. J. Clin. Oncol. 42, 8011 (2024).","journal-title":"J. Clin. Oncol."},{"key":"10925_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2021.08.011","volume":"157","author":"A Di Federico","year":"2021","unstructured":"Di Federico, A. et al. STK11\/LKB1 and KEAP1 mutations in non-small cell lung cancer: prognostic rather than predictive?. Eur. J. Cancer 157, 108\u2013113 (2021).","journal-title":"Eur. J. Cancer"},{"key":"10925_CR23","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis, F. et al. STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 8, 822\u2013835 (2018).","journal-title":"Cancer Discov."},{"key":"10925_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03498-9","volume":"24","author":"R Zhao","year":"2024","unstructured":"Zhao, R. et al. The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis. Cancer Cell Int. 24, 361 (2024).","journal-title":"Cancer Cell Int."},{"key":"10925_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.xjon.2023.10.016","volume":"16","author":"CN Fick","year":"2023","unstructured":"Fick, C. N. et al. Genomic profiling and metastatic risk in early-stage non-small cell lung cancer. JTCVS Open 16, 9\u201316 (2023).","journal-title":"JTCVS Open"},{"key":"10925_CR26","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1097\/PAS.0000000000000744","volume":"40","author":"K Kadota","year":"2016","unstructured":"Kadota, K. et al. KRAS mutation is a significant prognostic factor in early-stage lung adenocarcinoma. Am. J. Surg. Pathol. 40, 1579\u20131590 (2016).","journal-title":"Am. J. Surg. Pathol."},{"key":"10925_CR27","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.3390\/cells10113129","volume":"10","author":"E Pons-Tostivint","year":"2021","unstructured":"Pons-Tostivint, E. et al. STK11\/LKB1 modulation of the immune response in lung cancer: from biology to therapeutic impact. Cells 10, 3129 (2021).","journal-title":"Cells"},{"key":"10925_CR28","doi-asserted-by":"publisher","first-page":"113295","DOI":"10.1016\/j.celrep.2023.113295","volume":"42","author":"AM Zavitsanou","year":"2023","unstructured":"Zavitsanou, A. M. et al. KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance. Cell Rep. 42, 113295 (2023).","journal-title":"Cell Rep."},{"key":"10925_CR29","doi-asserted-by":"publisher","first-page":"507","DOI":"10.21037\/jtd-23-1017","volume":"16","author":"L Zhao","year":"2024","unstructured":"Zhao, L. et al. Prognosis of immunotherapy for non-small cell lung cancer with CDKN2A loss of function. J. Thorac. Dis. 16, 507\u2013515 (2024).","journal-title":"J. Thorac. Dis."},{"key":"10925_CR30","doi-asserted-by":"publisher","first-page":"216022","DOI":"10.1016\/j.canlet.2022.216022","volume":"554","author":"Y Tian","year":"2023","unstructured":"Tian, Y. et al. SMARCA4: current status and future perspectives in non-small-cell lung cancer. Cancer Lett. 554, 216022 (2023).","journal-title":"Cancer Lett."},{"key":"10925_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002242","volume":"9","author":"J Faget","year":"2021","unstructured":"Faget, J. et al. Neutrophils in the era of immune checkpoint blockade. J. Immunother. Cancer. 9, e002242 (2021).","journal-title":"J. Immunother. Cancer."},{"key":"10925_CR32","doi-asserted-by":"publisher","first-page":"8022","DOI":"10.1200\/JCO.2025.43.16_suppl.8022","volume":"43","author":"HA Wakelee","year":"2025","unstructured":"Wakelee, H. A. et al. IMpower010: genomic profiling and clinical outcomes with adjuvant atezolizumab in early-stage non-small cell lung cancer (eNSCLC). J. Clin. Oncol. 43, 8022 (2025).","journal-title":"J. Clin. Oncol."},{"key":"10925_CR33","doi-asserted-by":"publisher","first-page":"S374","DOI":"10.1016\/j.jval.2024.03.1743","volume":"27","author":"H Bailey","year":"2024","unstructured":"Bailey, H. et al. Healthcare resource utilization and health-related quality of life in patients with resectable non-metastatic non-small cell lung cancer treated with neoadjuvant chemotherapy in China: a real-world survey. Value Health 27, S374 (2024).","journal-title":"Value Health"},{"key":"10925_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10198-018-0955-5","volume":"20","author":"MF Janssen","year":"2019","unstructured":"Janssen, M. F. et al. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur. J. Health Econ. 20, 205\u2013216 (2019).","journal-title":"Eur. J. Health Econ."},{"key":"10925_CR35","doi-asserted-by":"publisher","first-page":"12765","DOI":"10.1002\/cam4.5920","volume":"12","author":"NA Mohindra","year":"2023","unstructured":"Mohindra, N. A. et al. General population reference values for the Functional Assessment of Cancer Therapy-Lung and PROMIS-29. Cancer Med. 12, 12765\u201312776 (2023).","journal-title":"Cancer Med."},{"key":"10925_CR36","first-page":"100298","volume":"3","author":"P Williams","year":"2022","unstructured":"Williams, P. et al. Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ): measurement properties and estimated clinically meaningful thresholds from a phase 3 study. JTO Clin. Res. Rep. 3, 100298 (2022).","journal-title":"JTO Clin. Res. Rep."},{"key":"10925_CR37","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0895-4356(01)00477-2","volume":"55","author":"D Cella","year":"2002","unstructured":"Cella, D. et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J. Clin. Epidemiol. 55, 285\u2013295 (2002).","journal-title":"J. Clin. Epidemiol."},{"key":"10925_CR38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1477-7525-5-70","volume":"5","author":"AS Pickard","year":"2007","unstructured":"Pickard, A. S. et al. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual. Life Outcomes 5, 70 (2007).","journal-title":"Health Qual. Life Outcomes"},{"key":"10925_CR39","doi-asserted-by":"publisher","first-page":"S1239","DOI":"10.1016\/j.annonc.2024.08.2291","volume":"35","author":"M Provencio Pulla","year":"2024","unstructured":"Provencio Pulla, M. et al. Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: clinical update from the phase III CheckMate 77T study. Ann. Oncol. 35, S1239\u2013S1240 (2024).","journal-title":"Ann. Oncol."},{"key":"10925_CR40","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","volume":"616","author":"C Abbosh","year":"2023","unstructured":"Abbosh, C. et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature 616, 553\u2013562 (2023).","journal-title":"Nature"},{"key":"10925_CR41","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","volume":"30","author":"JS Deutsch","year":"2024","unstructured":"Deutsch, J. S. et al. Association between pathologic response and survival after neoadjuvant therapy in lung cancer. Nat. Med. 30, 218\u2013228 (2024).","journal-title":"Nat. Med."},{"key":"10925_CR42","doi-asserted-by":"publisher","first-page":"CT097","DOI":"10.1158\/1538-7445.AM2025-CT097","volume":"85","author":"JS Deutsch","year":"2025","unstructured":"Deutsch, J. S. et al. Associations between percent residual viable tumor (%RVT) and efficacy with perioperative nivolumab (NIVO) for resectable NSCLC in CheckMate 77T. Cancer Res. 85, CT097 (2025).","journal-title":"Cancer Res."},{"key":"10925_CR43","first-page":"100384","volume":"3","author":"S Rosner","year":"2022","unstructured":"Rosner, S. et al. Association of pathologic complete response and long-term survival outcomes among patients treated with neoadjuvant chemotherapy or chemoradiotherapy for NSCLC: a meta-analysis. JTO Clin. Res. Rep. 3, 100384 (2022).","journal-title":"JTO Clin. Res. Rep."},{"key":"10925_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004574","volume":"22","author":"MMF Schuurbiers","year":"2025","unstructured":"Schuurbiers, M. M. F. et al. Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: a retrospective validation study. PLoS Med. 22, e1004574 (2025).","journal-title":"PLoS Med."},{"key":"10925_CR45","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jtho.2024.09.1443","volume":"20","author":"D Marinelli","year":"2025","unstructured":"Marinelli, D. et al. Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis. J. Thorac. Oncol. 20, 285\u2013295 (2025).","journal-title":"J. Thorac. Oncol."},{"key":"10925_CR46","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1158\/1078-0432.CCR-25-2958","volume":"32","author":"M Provencio","year":"2026","unstructured":"Provencio, M. et al. Minimal residual disease enhances prognostic stratification beyond pathologic response in resectable non-small cell lung cancer. Clin. Cancer Res. 32, 748\u2013755 (2026).","journal-title":"Clin. Cancer Res."},{"key":"10925_CR47","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","volume":"17","author":"B Ricciuti","year":"2022","unstructured":"Ricciuti, B. et al. Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status. J. Thorac. Oncol. 17, 399\u2013410 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"10925_CR48","doi-asserted-by":"publisher","first-page":"8012","DOI":"10.1200\/JCO.2024.42.16_suppl.8012","volume":"42","author":"MC Garassino","year":"2024","unstructured":"Garassino, M. C. et al. Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). J. Clin. Oncol. 42, 8012 (2024).","journal-title":"J. Clin. Oncol."},{"key":"10925_CR49","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1016\/S1556-0864(25)00382-X","volume":"20","author":"G Pasello","year":"2025","unstructured":"Pasello, G. et al. Patient-reported outcomes (PROs) with perioperative durvalumab in resectable NSCLC (AEGEAN). J. Thorac. Oncol. 20, S125\u2013S126 (2025).","journal-title":"J. Thorac. Oncol."},{"key":"10925_CR50","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.annonc.2025.10.018","volume":"37","author":"JS Deutsch","year":"2026","unstructured":"Deutsch, J. S. et al. Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort. Ann. Oncol. 37, 141\u2013154 (2026).","journal-title":"Ann. Oncol."},{"key":"10925_CR51","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s40291-023-00670-1","volume":"27","author":"J Zhao","year":"2023","unstructured":"Zhao, J. et al. Personalized cancer monitoring assay for the detection of ctDNA in patients with solid tumors. Mol. Diagn. Ther. 27, 753\u2013768 (2023).","journal-title":"Mol. Diagn. Ther."},{"key":"10925_CR52","doi-asserted-by":"publisher","unstructured":"Freed, D. et al. The Sentieon Genomics Tools\u2014a fast and accurate solution to variant calling from next-generation sequence data. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/115717 (2017).","DOI":"10.1101\/115717"},{"key":"10925_CR53","unstructured":"Broad Institute. Picard Toolkit. GitHub https:\/\/broadinstitute.github.io\/picard\/ (2019)."},{"key":"10925_CR54","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","volume":"581","author":"KJ Karczewski","year":"2020","unstructured":"Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434\u2013443 (2020).","journal-title":"Nature"},{"key":"10925_CR55","unstructured":"Van der Auwera, G. A. & O\u2019Connor, B. D. Genomics in the Cloud: using Docker, GATK and WDL in Terra (O\u2019Reilly Media, 2020)."},{"key":"10925_CR56","doi-asserted-by":"publisher","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","volume":"45","author":"SA Forbes","year":"2017","unstructured":"Forbes, S. A. et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 45, D777\u2013D783 (2017).","journal-title":"Nucleic Acids Res."},{"key":"10925_CR57","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giab008","volume":"10","author":"P Danecek","year":"2021","unstructured":"Danecek, P. et al. Twelve years of SAMtools and BCFtools. GigaScience 10, giab008 (2021).","journal-title":"GigaScience"},{"key":"10925_CR58","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","volume":"6","author":"P Cingolani","year":"2012","unstructured":"Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6, 80\u201392 (2012).","journal-title":"Fly (Austin)"},{"key":"10925_CR59","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/nar\/29.1.308","volume":"29","author":"ST Sherry","year":"2001","unstructured":"Sherry, S. T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308\u2013311 (2001).","journal-title":"Nucleic Acids Res."},{"key":"10925_CR60","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062\u2013D1067 (2018).","journal-title":"Nucleic Acids Res."},{"key":"10925_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00803-9","volume":"12","author":"X Liu","year":"2020","unstructured":"Liu, X. et al. dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs. Genome Med. 12, 103 (2020).","journal-title":"Genome Med."},{"key":"10925_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren, W. et al. The Ensembl variant effect predictor. Genome Biol. 17, 122 (2016).","journal-title":"Genome Biol."},{"key":"10925_CR63","unstructured":"Yang, H. vcf2maf v1.6.18. GitHub https:\/\/github.com\/mskcc\/vcf2maf (2018)."},{"key":"10925_CR64","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303 (2010).","journal-title":"Genome Res."},{"key":"10925_CR65","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ccell.2018.03.007","volume":"33","author":"AM Taylor","year":"2018","unstructured":"Taylor, A. M. et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell 33, 676\u2013689 (2018).","journal-title":"Cancer Cell"},{"key":"10925_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).","journal-title":"Genome Biol."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10925-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10925-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10925-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:51:20Z","timestamp":1792122680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10925-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":66,"journal-issue":{"issue":"8136","published-print":{"date-parts":[[2026,10,15]]}},"alternative-id":["10925"],"URL":"https:\/\/doi.org\/10.1038\/s41586-026-10925-6","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.C. reports advisory\/consulting fees from AstraZeneca, BioNTech, Bristol Myers Squibb, Caris Life Sciences, Daiichi Sankyo, Galvanize Therapeutics, Genentech, Johnson & Johnson, Merck, Moderna, Nuvalent, oNKo-Innate\/Audax, Pfizer, Regeneron and Summit Therapeutics; institutional research grant and\/or clinical research funding from AstraZeneca, Bristol Myers Squibb and Merck; and honoraria\/speaker fees from ASCO Post, Bio Ascend, Bristol Myers Squibb, Curio Science, IDEOlogy Health, MD Education, Medical Educator Consortium, Medscape, OMNI-Oncology, OncLive, Physicians\u2019 Education Resources, PeerView Institute, Revolution Medicines, Targeted Oncology and TRIPTYCH Health. M.M.A. reports advisory\/consulting fees from Merck, Pfizer, Bristol Myers Squibb, Foundation Medicine, Novartis, Gritstone Bio, Mirati Therapeutics, EMD Serono, AstraZeneca, Instil Bio, AstraZeneca, Regeneron, Janssen, Affini-T Therapeutics and Coherus BioSciences; travel support from Bristol Myers Squibb; and institutional research funding from Genentech\/Roche, Lilly, AstraZeneca, Bristol Myers Squibb and Amgen. J.D.S. reports speaker fees\/honoraria from AstraZeneca, Bristol Myers Squibb and Merck; advisory\/consulting fees from Merck, Bristol Myers Squibb, AstraZeneca, Roche and Regeneron; travel support from Merck, Bristol Myers Squibb and AstraZeneca; institutional research funding from Bristol Myers Squibb, Merck, AstraZeneca, CLS Therapeutics, Johnson & Johnson, Amgen, Boehringer Ingelheim and Pfizer. S.\u2009Lu reports speaker fees\/honoraria from AstraZeneca, Roche, Hansoh Pharma and Hengrui Therapeutics; advisory\/consulting fees from AstraZeneca, Pfizer, Boehringer Ingelheim, Hutchison MediPharma, Simcere, Zai Lab, GenomiCare, Yuhan, Roche, Menarini and InventisBio; leadership roles at Innovent Biologics, Simcere Zaiming Pharmaceutical and Shanghai Fosun Pharmaceutical; and institutional research funding from AstraZeneca, Hutchison MediPharma, Bristol Myers Squibb, Hengrui Therapeutics, BeiGene, Roche, Hansoh Pharma and Lilly Suzhou Pharmaceutical Company. F.T. reports speaker fees\/honoraria from Merck Sharp & Dohme, Bristol Myers Squibb, Boehringer Ingelheim Japan, Ono Pharmaceutical, Johnson & Johnson, Covidien Japan, Taiho Pharmaceutical, Eli Lilly Japan, AstraZeneca, Chugai Pharmaceutical, Kyowa-Kirin, Takeda Pharmaceutical, Pfizer, Olympus, Stryker and Intuitive Japan; advisory\/consulting fees from AstraZeneca, Chugai Pharmaceutical and Ono Pharmaceutical; and institutional research funding from Boehringer Ingelheim Japan, Ono Pharmaceutical, Taiho Pharmaceutical, Eli Lilly Japan and Chugai Pharmaceutical. R.C. reports speaker fees\/honoraria from Daiichi-Sankyo, AstraZeneca and Pfizer; advisory\/consulting fees from Bristol Myers Squibb and Pierre Fabre; and institutional research funding from Bristol Myers Squibb. T.-E.C. reports speaker fees\/honoraria from Amgen, Pfizer, Merck Sharp & Dohme, Servier, Merck Serono, Bristol Myers Squibb, AstraZeneca and Takeda; advisory\/consulting fees from Amgen, Pfizer, Merck Sharp & Dohme, Servier, Merck Serono, Bristol Myers Squibb, AstraZeneca and Takeda; travel support from Amgen, Pfizer, Merck Sharp & Dohme, Servier, Merck Serono, Bristol Myers Squibb, AstraZeneca and Takeda; and institutional research funding from Amgen, Pfizer, Merck Sharp & Dohme, Merck Serono, Roche, AstraZeneca and Takeda. S.\u2009Bohet reports advisory\/consulting fees from Bristol Myers Squibb. J.M.T. reports advisory\/consulting fees from Akoya Biosciences\/Quanterix, Bristol Myers Squibb, Elephas, Genentech\/Roche, Merck, Moderna, NextPoint Therapeutics and Regeneron; stock ownership for Akoya Biosciences\/Quanterix; and institutional research funding from Akoya Biosciences\/Quanterix and Bristol Myers Squibb. J.S.D. reports speaker fees\/honoraria from PeerView; patent ownership for a machine-learning algorithm for pathologic response assessment; and institutional research funding from Bristol Myers Squibb and NextPoint Therapeutics. C.C.E. reports employment at Bristol Myers Squibb and stock ownership for Bristol Myers Squibb. S.M.-S. reports employment at Bristol Myers Squibb and stock ownership for Bristol Myers Squibb. J.N. reports employment at Bristol Myers Squibb and stock ownership for Bristol Myers Squibb. V.I. reports employment at Bristol Myers Squibb and stock ownership for Bristol Myers Squibb. Y.-H.H. reports employment at Bristol Myers Squibb and stock ownership for Bristol Myers Squibb. P.S. reports employment at Bristol Myers Squibb and stock ownership for Bristol Myers Squibb. S.\u2009Bhatia reports travel support from Bristol Myers Squibb; employment at Bristol Myers Squibb; stock ownership for Bristol Myers Squibb; and other financial\/non-financial interests from Bristol Myers Squibb. K.C. reports employment at Bristol Myers Squibb and stock ownership for Bristol Myers Squibb. S.I.B. reports employment at Bristol Myers Squibb and stock ownership for Bristol Myers Squibb. S.\u2009Lucherini reports employment at Bristol Myers Squibb and stock ownership for Bristol Myers Squibb. N.E. reports employment at Bristol Myers Squibb and stock ownership for Bristol Myers Squibb. A.Y. reports employment at Bristol Myers Squibb and stock ownership for Bristol Myers Squibb. M.P. reports speaker fees\/honoraria from Bristol Myers Squibb, AstraZeneca, Merck Sharp & Dohme, Roche, Takeda, Eli Lilly, F. Hoffmann-La Roche, Janssen, Pfizer and Amgen; advisory\/consulting fees from Bristol Myers Squibb, AstraZeneca, Merck Sharp & Dohme, Roche, Takeda, Eli Lilly, F. Hoffmann-La Roche, Janssen, Pfizer, Amgen, Daiichi Sankyo, Johnson & Johnson, Gilead, Guardant Health, Ipsen, Incyte Biosciences, Bayer, Pharmacosmos, Astellas Pharma and Aegean Pharmaceuticals; leadership roles at Instituto Investigaci\u00f3n Sanitaria Puerta de Hierro\u2013Segovia de Arana, Grupo Espa\u00f1ol de C\u00e1ncer de Pulm\u00f3n and Grupo Oncol\u00f3gico para el Tratamiento de las Enfermedades Linfoides; travel support from Bristol Myers Squibb, AstraZeneca, Merck Sharp & Dohme, Roche, Takeda, Eli Lilly, F. Hoffmann-La Roche, Janssen, Pfizer, Amgen, Boehringer Ingelheim and Pierre Fabre; and institutional research funding from Bristol Myers Squibb, AstraZeneca, Merck Sharp & Dohme, Roche, Takeda, Pfizer, Boehringer Ingelheim, Amgen, Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, European Commission, Eli Lilly, F. Hoffmann-La Roche, Janssen and Pierre Fabre. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}